NNVC (Nanoviricides) YoY EBITDA Growth: 31.75% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NNVC Nanoviricides Inc NNVC
35 GF Score
Price $1.55
View Full Analysis

What is Nanoviricides YoY EBITDA Growth?

Nanoviricides NNVC +1.97% 35 YoY EBITDA Growth is 31.75% as of Mar. 2026. GuruFocus rates NNVC with a GF Score™ of 35/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Nanoviricides's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 31.75%.

Nanoviricides's EBITDA per Share for the three months ended in Mar. 2026 was $-0.09.

Nanoviricides YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Nanoviricides's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanoviricides YoY EBITDA Growth Chart

Nanoviricides Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.29 13.16 -5.31 6.38 8.56

Nanoviricides Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.64 32.20 55.30 16.67 31.75
NNVC
35GF Score
Nanoviricides Inc NNVC
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanoviricides YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Nanoviricides's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(-0.577--0.631)/ | -0.631 |
=8.56 %

Nanoviricides's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-0.086--0.126)/ | -0.126 |
=31.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 31.75% mean?
Nanoviricides (NNVC) has a YoY EBITDA Growth of 31.75% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Nanoviricides and its competitors.
Is Nanoviricides' YoY EBITDA Growth too high?
Nanoviricides' current YoY EBITDA Growth is 31.75%. Overall, Nanoviricides has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Nanoviricides' YoY EBITDA Growth compare to LITS and ESLA?
Nanoviricides' YoY EBITDA Growth of 31.75% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Nanoviricides and its competitors. Nanoviricides's current YoY EBITDA Growth is 31.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanoviricides stock overvalued right now?
Nanoviricides (NNVC) has a current YoY EBITDA Growth of 31.75%. The current YoY EBITDA Growth is 31.75%. Nanoviricides' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Nanoviricides (NNVC), the current YoY EBITDA Growth is 31.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanoviricides Business Description

Other Exchanges NV3P:Germany
Address 1 Controls Drive, Shelton, CT, USA, 06484
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
35GF Score

Get the complete analysis for NNVC

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price